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Negative lymph node count is an
independent prognostic factor for patients
with rectal cancer who received
preoperative radiotherapy
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Abstract
Background: Negative lymph node (NLN) count has been reported to provide more accurate prognostic
information than the N stage alone in patients with rectal cancer (RC). Since preoperative radiotherapy (Pre-RT) can
significantly affect the LN status, it is unclear whether NLN count still has prognostic value count on survival of
patients with RC who received Pre-RT.
Methods: In this study, clinicopathological characteristics, number of positive LNs and survival time were collected
from Surveillance, Epidemiology, and End Results Program (SEER)-registered RC patients. Univariate and multivariate
Cox proportional hazards models were used to assess the risk factors for survival.
Results: X-tile plots identified 9 (P < 0.001) as the optimal cutoff NLN value to divide the patients into high and
low risk subsets in terms of cause specific survival (CSS). NLN count was validated as independently prognostic
factor in univariate and multivariate analysis (P < 0.001). Subgroup analysis showed that NLN count was an
independently prognostic factor for patients with stage ypII (P = 0.002) and ypIII (P < 0.001).
Conclusions: Our results firmly demonstrated that NLN count provides accurate prognostic information for RC
patients with Pre-RT.
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Background
Rectal cancer (RC) is one of the most common malig-
nancies in the USA, and the incidence of RC in Asian
countries is increasing rapidly and has been considered
to be similar to that of the Western countries [1].
Preoperative radiotherapy (Pre-RT) has become part of
standard practice offered to improve treatment out-
comes in patients with RC because of the oncologic
benefit of reduced local recurrence rate [2]. But till now,
there is still lack of effective means for accurate prog-
nostic evaluation on the survival.
It is widely thought that lymph node (LN) metasta-
sis indicates worse tumor response grade and poorer
survival. According to the guidelines for RC from the
National Comprehensive Cancer Network, a minimum
of twelve lymph nodes must be retrieved and exam-
ined for accurate staging and the number of meta-
static LNs was validated as an independent prognostic
factors [3]. While the node-positive patients with RC
are heterogeneous and the prognosis of these patients
cannot be stratified by the node-stage only [3, 4].
Therefore, the concept of negative lymph node (NLN)
counts has attracted attention recently as a prognostic
indicator in various cancers, including breast [5], cer-
vical [6], and esophagus [7]. It has been reported that
the number of NLNs was an independent prognostic
factor for patients with colon cancer [8]. However,
Pre-RT can yield tumor downstaging, reduce the
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burden of residual microscopic disease at surgery and
reduce the number of LNs retrieved in operation [9].
With the decreased LNs retrieval, the prognostic
value of the LN count might also diminish [10]. It
has been reported that increased number of NLNs is
associated with improved survival in pathological IIIB
and IIIC RC treated with Pre-RT [7]. While it is still
unclear whether NLN still has prognostic value count
on survival of all patients with RC, including stage I
and II, who received Pre-RT. The purpose of this
study was to assess the association between NLN
count and survival of patients with RC of all stages
who received Pre-RT. In order to get convincing re-
sults in a larger series patients, we used the SEER
(Surveillance, Epidemiology and End Results)-regis-
tered database to analyze this association, and deter-
mine the optimal cutoff value of NLN count.
Methods
Study population and data extracted
The SEER (Surveillance, Epidemiology, and End
Results Program) database and SEER-stat software
(SEER Stat 8.3.2) were used to identify patients
whose pathological diagnosis as RC between 2004
and 2010. Only patients who underwent Pre-RT and
surgical treatment with age of diagnosis more than
18 years were included. Histological type were limited
to adenocarcinoma (8140/3), carcinoma (8010/3; 8020/3;
8021/3 and 8145/3) and signet ring cell carcinoma
(8490/3). Patients were excluded if they had only local
excision following Pre-RT, multiple primary malignant
neoplasms, incomplete TNM staging, with distant me-
tastasis (M1), no evaluation on LNs, died within
30 days after surgery or information on CSS and sur-
vival months unavailable.
Year of diagnosis, age, sex, race, grade, histologic type,
ypT stage, number of LNs examined, number of positive
LNs and CSS were assessed. TNM classification was
restaged according to the criteria described in the AJCC
Cancer Staging Manual (7th edition, 2010).
Statistical analysis
The NLNs cutoff points were determined using the
X-tile program, which identified the cutoff value
Table 1 Univariate analysis of the influence of different NLN count on CSS in RC patients who received Pre-RT
LNs No. 5-year CCS χ2 P value LNs No. 5-year CCS χ2 P value
≤0 72 51.8% 41.745 0.000 ≤12 3685 76.5% 42.763 0.000
>0 5996 79.5% >12 2383 83.3%
≤1 230 63.5% 50.100 0.000 ≤13 4022 76.9% 38.747 0.000
>1 5838 79.7% >13 2046 83.6%
≤2 444 68.2% 44.132 0.000 ≤14 4320 77.3% 33.939 0.000
>2 5624 80.0% >14 1748 83.7%
≤3 720 69.0% 54.496 0.000 ≤15 4585 77.3% 36.435 0.000
>3 5348 80.5% >15 1483 84.8%
≤4 1015 70.0% 67.375 0.000 ≤16 4822 77.6% 33.037 0.000
>4 5053 81.0% >16 1246 85.3%
≤5 1314 71.8% 68.432 0.000 ≤17 5013 72.8% 27.827 0.000
>5 4754 81.2% >17 1055 85.4%
≤6 1625 72.5% 74.979 0.000 ≤18 5177 78.0% 23.546 0.000
>6 4443 81.6% >18 891 85.5%
≤7 1974 73.5% 74.302 0.000 ≤19 5302 78.0% 25.448 0.000
>7 4094 81.9% >19 766 86.8%
≤8 2285 74.2% 70.405 0.000 ≤20 5422 78.2% 25.257 0.000
>8 3783 82.1% >20 646 87.2%
≤9 2613 74.3% 78.060 0.000 ≤21 5528 77.9% 21.120 0.000
>9 3455 82.8% >21 540 87.5%
≤10 2973 75.0% 67.236 0.000 ≤22 5606 78.4% 21.730 0.000
>10 3095 83.1% >22 462 88.0%
≤11 3320 75.6% 57.663 0.000 ≤23 5671 78.5% 18.872 0.000
>11 2748 83.4% >23 397 88.8%
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Table 2 Comparison of clinical characteristics of patients with NLN ≤ 9 or NLN > 9
Characteristic Total NLN ≤ 9 NLN > 9 P value
6068 2613 3455
Follow up Median (IQU) 58 (42-81) months
Year of diagnosis 0.000
2004–2007 3122 1553 1569
2008–2010 2946 1060 1886
Sex 0.007
Male 3881 1625 2256
Female 2187 988 1199
Age 0.000
<60 3368 1365 2003
≥60 2700 1248 1452
Race 0.593
White 4927 2137 2790
Black 511 214 297
Others 630 262 368
Grade 0.222
Grade I/ II 5098 2184 2914
Grade III/ IV 970 429 541
Histologic type 0.430
Adenocarcinoma 5517 2367 3150
Mucinous adenocarcinoma 490 215 275
Signet ring cell carcinoma 61 31 30
ypT stage 386 189 197 0.062
1 957 425 532
2 4306 1820 2486
3 419 179 240
4
LNs dissected 12.79 6.92 17.23 0.000
Fig. 1 X-tile analysis of survival data from the SEER registry. X-tile analysis was performed using patient data, equally divided into training and
validation sets, from the SEER registry. In X-tile plots of the training sets (a), the plots of matched validation sets are shown in the smaller inset.
The optimal cut-point highlighted by the black circle (a) is shown on a histogram of the entire cohort (b), and a Kaplan-Meier plot (c). P values
were determined using the cutoff point defined in the training set and applying it to the validation set. (The optimal cutoff value for NLN count
is 9, χ2 = 78.060, P < 0.001)
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with the minimum P values from log-rank χ2 statis-
tics for the categorical NLNs in terms of CSS. Base-
line characteristics were compared using the X2 test
for nominal variables. Survival curves were generated
using Kaplan-Meier analyses, and the differences be-
tween the curves were analyzed by log-rank test.
Cox regression models were built for analysis of risk
factors for survival outcomes. Statistical analyses
were performed using the statistical software package
SPSS for Windows, version 19.0 (SPSS Inc., Chicago,
IL). All P values were two-sided. P < 0.05 was con-
sidered statistically significant.
Results
Patient characteristics from SEER database
In SEER database, we selected a total of 6068 patients
with RC who received Pre-RT, including 3881 male and
2187 female from 2004 to 2010. The median age of pa-
tients was 59 years. There were 4042 patients with stage
ypN0, 1352 with stage ypN1 and 674 with stage ypN2.
The optimal cutoff value for NLN count calculated by
X-tile
To assess the influence of different NLN count on
CSS, we analyzed the individual result using different
Table 3 Univariate and multivariate survival analyses of RC patients who received Pre-RT
Characteristic 5-year CCS Univariate analysis Multivariate analysis
χ2 test P HR(95%CI) P
Year of diagnosis 2.412 0.120 NI
2004–2007 78.4%
2008–2010 80.2%
Sex 1.655 0.198 NI
Male 29.5%
Female 78.4%
Age 21.805 0.000 0.000
< 60 81.3% Ref
≥ 60 76.4% 0.777 (0.697 ~ 0.866) 0.000
Race 14.873 0.000 0.909
White 79.5% Ref
Black 72.7% 1.129 (0.937 ~ 1.364) 0.202
Others 81.8% 1.585 (1.246 ~ 2.017) 0.000
Grade 112.363 0.000 0.000
Grade I/ II 81.5% Ref
Grade III/ IV 66.9% 0.596 (0.523 ~ 0.680) 0.000
Histologic type 81.128 0.000 0.000
Adenocarcinoma 80.4% Ref
Mucinous adenocarcinoma 69.2% 0.412 (0.308 ~ 0.635) 0.000
Signet ring cell carcinoma 32.5% 0.601 (0.408 ~ 0.885) 0.010
ypT stage 148.323 0.000 0.000
1 88.6% Ref
2 87.9% 0.293 (0.212 ~ 0.405) 0.000
3 77.9% 0.303 (0.239 ~ 0.384) 0.000
4 62.6% 0.584 (0.494 ~ 0.692) 0.000
LNs 2.234 0.135 NI
≤ 12 78.5%
> 12 79.8%
NLN 78.060 0.000 0.000
≤ 9 74.3% Ref
> 9 82.8% 1.623 (1.457 ~ 1.809) 0.000
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Fig. 2 Log-rank tests of CSS comparing patients with NLNs (<9 VS ≥9) for (a) stage ypI: P = 0.008; (b) stage ypII: P < 0.001; and (c) stage ypIII: P <0.001
Table 4 Univariate and multivariate survival analyses of stage ypI RC patients who received Pre-RT
Characteristic 5-year CCS Univariate analysis Multivariate analysis
χ2 test P HR(95%CI) P
Year of diagnosis 6.324 0.012 0.035
2004–2007 87.9% Ref
2008–2010 92.2% 1.609 (1.029 ~ 2.517) 0.037
Sex 1.238 0.266 NI
Male 90.0%
Female 89.3%
Age 2.359 0.125 NI
< 60 91.3%
≥ 60 88.0%
Race 6.222 0.045 0.053
White 88.9% Ref
Black 81.0% 3.792 (1.201 ~ 11.968) 0.023
Others 98.9% 4.392 (1.251 ~ 15.415) 0.021
Grade 0.483 0.487 NI
Grade I/ II 90.0%
Grade III/ IV 85.1%
Histologic type 3.218 0.200 NI
Adenocarcinoma 89.8%
Mucinous adenocarcinoma 89.5%
Signet ring cell carcinoma 50.0%
ypT stage 0.001 0.972 NI
1 90.5%
2 89.4%
LNs 9.401 0.002 0.284
≤ 12 87.8% Ref
> 12 93.4% 1.702 (0.949 ~ 3.052) 0.074
NLN 7.080 0.008 0.600
≤ 9 87.6% Ref
> 9 91.6% 1.128 (0.682 ~ 1.866) 0.638
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NLN count ranging from 0 to 23. The 5-year CSS
was calculated for patients with N (NLNs number) or
more nodes and less than N nodes. As shown in
Table 1, NLN count in patients with RC who received
Pre-RT was a prognosis factor for number ranging
from 0 to 23. With the NLN count increased from 0
to 23, the 5-year CSS rate increased from 51.8 to
88.8% (Table 1). Next X-tile plots were constructed
and the maximum χ2 log-rank value of 78.060 (the
number as 9, Fig. 1, P < 0.001) was produced, apply-
ing 9 as the optimal cutoff value to divide the cohort
into high and low risk subsets in terms of CSS. There
was a significant improvement in 5-year CSS between
two subsets (74.3% v.s. 82.8%, Table 1). As shown in
Table 2, the year of diagnosis, sex, age and the
average number of LNs dissected were significantly
different between patients with NLN ≤ 9 or >9
(P < 0.05).
Impact of the NLN count on CSS in RC patients who
received Pre-RT
According to univariate analysis, age (≥ 60), race (black
persons), grade (III/IV), histologic type (signet ring cell
carcinoma), ypT stage (ypT3 and ypT4) and NLNs (≤ 9)
were associated with poor outcomes in patients with RC
who received Pre-RT (P < 0.001) (Table 3). In multi-
variate Cox analysis, age, grade, histologic type, ypT
stage and NLN counts were independently prognostic
factors (P < 0.001, Table 3). NLN counts (> 9) exhibited
Table 5 Univariate and multivariate survival analyses of stage ypII RC patients who received Pre-RT
Characteristic 5-year CCS Univariate analysis Multivariate analysis
χ2 test P HR(95%CI) P
Year of diagnosis 0.255 0.614 NI
2004–2007 84.1%
2008–2010 84.7%
Sex 1.414 0.234 NI
Male 85.1%
Female 83.0%
Age 21.435 0.000 0.000
< 60 87.2% Ref
≥ 60 81.1% 0.677 (0.566 ~ 0.810) 0.000




Grade 24.552 0.000 0.000
Grade I/ II 85.6% Ref
Grade III/ IV 76.2% 0.599 (0.479 ~ 0.748) 0.000
Histologic type 6.705 0.035 0.042
Adenocarcinoma 85.0% Ref
Mucinous adenocarcinoma 75.9% 0.786 (0.249 ~ 2.481) 0.682
Signet ring cell carcinoma 71.6% 1.103 (0.339 ~ 3.590) 0.871
ypT stage 21.301 0.000 0.000
3 85.4% Ref
4 73.2% 0.591 (0.445 ~ 0.767) 0.000
LNs 9.648 0.002 0.892
≤ 12 82.5% Ref
> 12 86.7% 0.983 (0.749 ~ 1.289) 0.900
NLN 20.806 0.000 0.002
≤ 9 80.9% Ref
> 9 86.5% 1.520 (1.170 ~ 1.975) 0.002
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a favorable effect on survival (HR = 1.623, 95% CI
1.457 ~ 1.809, P < 0.001, Table 3).
Impact of the NLN count on CSS in RC patients based on
each pathological grade
We then further analyzed of the effects of NLN on sur-
vival in each subgroup of stage yp I, yp II and yp III. As
shown in Fig. 2, subgroup analysis showed that NLN was
a prognosis factor for patients with RC who received Pre-
RT in stage ypI (χ2 = 7.080; P = 0.008), ypII (χ2 = 20.806;
P < 0.001) and ypIII (χ2 = 33.138; P < 0.001), respectively.
Moreover, as shown in Tables 4, 5 and 6, the NLN count
was also an independently prognostic factor in stage ypII
(HR: 1.520, 95%CI: 1.170 ~ 1.975; P = 0.002) and ypIII
(HR: 1.466, 95%CI: 1.264 ~ 1.700; P < 0.001) after adjust-
ment for potential confounders.
Discussion
LN metastasis is considered as one of the most signifi-
cant prognostic factors in RC [11]. The total number of
LNs retrieved is fundamental in most pathological sta-
ging systems for RC. Inadequate LN evaluation is associ-
ated with worse outcomes in terms of tumor recurrence
and patient survival [12]. Thus, looking for effective
means of assessment of LNs on survival can provide
more accurate prognostic information.
Table 6 Univariate and multivariate survival analyses of stage ypIII RC patients who received Pre-RT
Characteristic 5-year CCS Univariate analysis Multivariate analysis
χ2 test P HR(95%CI) P
Year of diagnosis 0.038 0.846 NI
2004–2007 65.6%
2008–2010 67.0%
Sex 0.026 0.872 NI
Male 65.9%
Female 66.2%
Age 17.245 0.000 0.000
< 60 69.3% Ref
≥ 60 60.9% 0.747 (0.654 ~ 0.866) 0.000
Race 17.535 0.000 0.625
White 66.8% Ref
Black 51.6% 1.125 (0.880 ~ 1.436) 0.347
Others 71.3% 1.767 (1.290 ~ 2.421) 0.000
Grade 41.722 0.000 0.000
Grade I/ II 69.5% Ref
Grade III/ IV 53.9% 0.670 (0.566 ~ 0.794) 0.000
Histologic type 24.617 0.000 0.037
Adenocarcinoma 67.4% Ref
Mucinous adenocarcinoma 60.7% 0.562 (0.378 ~ 0.836) 0.004
Signet ring cell carcinoma 41.8% 0.588 (0.383 ~ 0.904) 0.016
ypT stage 66.241 0.000 0.000
1 73.0% Ref
2 83.7% 0.442 (0.242 ~ 0.810) 0.008
3 65.1% 0.276 (0.195 ~ 0.391) 0.000
4 46.8% 0.564 (0.451 ~ 0.704) 0.000
LNs 1.975 0.160 NI
≤ 12 64.9%
> 12 67.0%
NLN 33.138 0.000 0.000
≤ 9 60.5% Ref
> 9 71.4% 1.466 (1.264 ~ 1.700) 0.000
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According to the AJCC-7 RC staging system, a 12-
node minimum is required for proper tumor stage and
associated with a good survival outcome in patients
treated with surgery [3]. Yet, the number of positive LN
is often affected by many facts such as neoadjuvant ther-
apy, and the number of LN retrieved and inspected [3].
Once the range of LN retrieved is not enough, the pre-
diction of survival would be inaccurate. Therefore, the
concept of NLN has been developed recently. NLN
count has a unique advantage that it is little influenced
by the number of LN retrieved [13]. The more NLN
count is, the better the survival would be. Li et al. [12]
reported that the optimal cutoff value of 10 was vali-
dated as an independent prognostic factor in stage
ypIIIB and ypIIIC RC patients treated with Pre-RT. In
this study, we found that the NLN count was an inde-
pendent prognosis factor for all patients with RC who
received Pre-RT. And we identified the optimal cutoff
value for NLN count as 9. Obviously, NLN count is a
good supplement for LN stage and TNM stage on evalu-
ating the prognosis of patients with RC who received
Pre-RT, respectively for patients with stage ypI, ypII and
ypIII. Until now, there has been no report confirming
the mechanism of NLNs influencing on the prognosis of
RC. But it is suggested that lymphatic micrometastasis is
a key etiology of recurrence and metastasis after resec-
tion of RC [14]. LN micrometastasis, is common in
nodes with the size ranging from 0.2 to 2.0 mm which
determined to be negative by HE staining, but positive
for cytokeratin (CK) by immunohistochemical staining
[15]. Because it is difficult to find lymphatic micrometas-
tasis during operation, we can retrieve more NLNs to
reduce the residual micrometastases, in order to im-
prove the prognosis of RC.
The intended purpose of Pre-RT is tumor down-
staging by decreasing the primary tumor bulk and redu-
cing the burden of residual associated LN metastases at
surgery, thus increasing the potential of margin-negative
resections [9]. It has been reported that Pre-RT may
cause radiation-induced lymphocyte destruction and stro-
mal fibrosis resulting in alterations of the morphology of
the LNs, making LN detection during operation more
difficult [9]. Some researchers found that a decreased LN
count after Pre-RT was related to good survival [16, 17].
The NLN count is particularly useful in the predic-
tion of survival because it is little influenced by the
number of LN retrieved, and has potential to reflect
the dissection of lymphatic micrometastasis. In this
study, we revealed that NLN count was an independ-
ent prognostic factor for patients with RC who re-
ceived Pre-RT. Subgroup analysis showed that NLN
was a prognosis factor for patients with RC who re-
ceived Pre-RT in stage ypI (χ2 = 7.080; P = 0.008),
ypII (χ2 = 20.806; P < 0.001) and ypIII (χ2 = 33.138;
P < 0.001), respectively. It might provide more accur-
ate prognostic information than the N stage alone in
patients with Pre-RT.
This study has several limitations. First, the SEER
database does not include information of therapeutic
options such as detailed information of chemotherapy,
targeted therapy, immunotherapy, recurrence and me-
tastasis, which may also impact patients’ prognosis. Sec-
ond, this data lack detailed description of preoperative
clinical grading and the information about tumor and
LN recession response to treatment, and our analyses
could not adjust for these potential confounding factor.
Third, different operative approaches, doctors and even
pathologist would affect the detective rate of total LN
and metastatic LN, but the SEER do not include these
information [10]. Although future clinical research will
be required to confirm the role of NLN, our study has
its convincing power for it is one of the largest popula-
tion based study until now.
Conclusions
Our results firmly demonstrated that NLN count was an
independent prognostic factor for patients with RC who
received Pre-RT. It could provide more accurate prog-
nostic information for RC patients with Pre-RT (stage
ypI, ypII and ypIII, respectively).
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